CD274 and neoplasm: Finally, navoximod either as a single or dual therapy with PD‐L1 antibodies yielded only modest efficacy in clinical trials, despite the high potency of navoximod in priming anti‐tumor immune activity, highlighting the insufficient tumor bioavailability of this potent molecule in the current administration paradigm.13, 16